<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Glucotrack Inc — News on 6ix</title>
<link>https://6ix.com/company/glucotrack-inc</link>
<description>Latest news and press releases for Glucotrack Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/glucotrack-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835761878dffbe2df0f7163.webp</url>
<title>Glucotrack Inc</title>
<link>https://6ix.com/company/glucotrack-inc</link>
</image>
<item>
<title>Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-publication-of-peer-reviewed-study-supporting-long-life-sensor-design-for-implantable-continuous-blood-glucose-monitoring-technology</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-publication-of-peer-reviewed-study-supporting-long-life-sensor-design-for-implantable-continuous-blood-glucose-monitoring-technology</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and functionality of design in the latter stage of in-human useRUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with di</description>
</item>
<item>
<title>Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent</description>
</item>
<item>
<title>Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-to-file-significant-ide-with-fda-for-us-clinical-trial-in-early-q2-based-on-critical-2025-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-to-file-significant-ide-with-fda-for-us-clinical-trial-in-early-q2-based-on-critical-2025-milestones</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM</description>
</item>
<item>
<title>Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-to-present-at-lsi-usa-26-medtech-innovation-summit</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-to-present-at-lsi-usa-26-medtech-innovation-summit</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the</description>
</item>
<item>
<title>Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-uspto-approval-issuance-130100534</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-uspto-approval-issuance-130100534</guid>
<pubDate>Thu, 29 Jan 2026 13:01:00 GMT</pubDate>
<description>RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company’s continuous blood glucose monitoring (CBGM) platform. The patents strengthen Glucotrack’s competitiv</description>
</item>
<item>
<title>Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-inc-announces-pricing-4-130000254</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-inc-announces-pricing-4-130000254</guid>
<pubDate>Tue, 30 Dec 2025 13:00:00 GMT</pubDate>
<description>Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares</description>
</item>
<item>
<title>Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-reports-third-quarter-2025-210500977</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-reports-third-quarter-2025-210500977</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glu</description>
</item>
<item>
<title>Glucotrack, Inc. Encourages Shareholders to Vote</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-inc-encourages-shareholders-vote-210500347</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-inc-encourages-shareholders-vote-210500347</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will reconvene a Special Meeting of Shareholders (the “Special Meeting”) on November</description>
</item>
<item>
<title>Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-appoints-neuromodulation-painful-diabetic-200500180</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-appoints-neuromodulation-painful-diabetic-200500180</guid>
<pubDate>Wed, 29 Oct 2025 20:05:00 GMT</pubDate>
<description>Renowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoringRUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been</description>
</item>
<item>
<title>Glucotrack, Inc. Reminds Shareholders to Vote</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-inc-reminds-shareholders-vote-120000399</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-inc-reminds-shareholders-vote-120000399</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will hold a Special Meeting of Shareholders (the “Special Meeting”) on October 31, 2025, a</description>
</item>
<item>
<title>Glucotrack to Participate in the Q3 Virtual Investor Summit</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-participate-q3-virtual-investor-120000909</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-participate-q3-virtual-investor-120000909</guid>
<pubDate>Thu, 11 Sep 2025 12:00:00 GMT</pubDate>
<description>RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025. Presentation detailsPresenter: Paul V. Goode, PhD, President and Chief Execu</description>
</item>
<item>
<title>Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-reports-second-quarter-2025-200500579</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-reports-second-quarter-2025-200500579</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinica</description>
</item>
<item>
<title>Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-expands-clinical-advisory-team-123000216</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-expands-clinical-advisory-team-123000216</guid>
<pubDate>Wed, 06 Aug 2025 12:30:00 GMT</pubDate>
<description>Experienced cardiac electrophysiologist joins Glucotrack’s growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestonesRUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that David S. Hirsh, MD, has joined the Company’s clinical advisory team as Medical Director – Card</description>
</item>
<item>
<title>Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-exhibit-2025-association-diabetes-123000494</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-exhibit-2025-association-diabetes-123000494</guid>
<pubDate>Thu, 31 Jul 2025 12:30:00 GMT</pubDate>
<description>Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot studyRUTHERFORD, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will participate in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting to be held on August 8-11, 2025 in Phoenix,</description>
</item>
<item>
<title>Glucotrack Announces Repurchase of Series A Warrants</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-repurchase-series-warrants-123000853</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-repurchase-series-warrants-123000853</guid>
<pubDate>Tue, 08 Jul 2025 12:30:00 GMT</pubDate>
<description>Warrant buyback extinguishes warrant liability accounting and share dilution overhangRUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The repurchase was completed as part of the Company’s capital</description>
</item>
<item>
<title>Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-onetwo-analytics-present-positive-123000940</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-onetwo-analytics-present-positive-123000940</guid>
<pubDate>Wed, 25 Jun 2025 12:30:00 GMT</pubDate>
<description>Comprehensive analysis confirms safety and strong accuracy of Glucotrack's innovative blood-based continuous glucose monitoring technology, with MARD of 7.7%RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results from its completed first-in-human clinical study presented at the American Diabetes Assoc</description>
</item>
<item>
<title>Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-reverse-stock-split-130500232</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-announces-reverse-stock-split-130500232</guid>
<pubDate>Thu, 12 Jun 2025 13:05:00 GMT</pubDate>
<description>1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001</description>
</item>
<item>
<title>Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management</title>
<link>https://6ix.com/company/glucotrack-inc/news/rebuilding-trust-how-glucotrack-is-establishing-a-new-standard-in-diabetes-management</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/rebuilding-trust-how-glucotrack-is-establishing-a-new-standard-in-diabetes-management</guid>
<pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
<description>By JE Insights, Benzinga DETROIT, MICHIGAN - June 10, 2025 (NEWMEDIAWIRE) - While the genesis of typical modern medical technologies focuses on a specific</description>
</item>
<item>
<title>Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions</title>
<link>https://6ix.com/company/glucotrack-inc/news/glucotrack-showcase-long-term-continuous-123000570</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/glucotrack-showcase-long-term-continuous-123000570</guid>
<pubDate>Wed, 04 Jun 2025 12:30:00 GMT</pubDate>
<description>Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will present safety and performance d</description>
</item>
<item>
<title>Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives</title>
<link>https://6ix.com/company/glucotrack-inc/news/upcoming-benzinga-webinar-with-glucotrack-to-discuss-the-potential-of-its-innovative-cbgm-technology-to-transform-diabetes-care-and-patient-lives</link>
<guid isPermaLink="true">https://6ix.com/company/glucotrack-inc/news/upcoming-benzinga-webinar-with-glucotrack-to-discuss-the-potential-of-its-innovative-cbgm-technology-to-transform-diabetes-care-and-patient-lives</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>By Meg Flippin Benzinga Glucotrack will host a virtual webinar discussing its Continuous Blood Glucose Monitor (CBGM) innovation on May 29 at 11 am ET. The</description>
</item>
</channel>
</rss>